

The Strategic Research and Innovation Agenda for Personalised Medicine, SRIA for PM

The European Partnership for Personalised Medicine, EP PerMed

Speakers

Dr. Monika Frenzel, ANR, France
Dr. Wolfgang Ballensiefen, DLR, Germany

The Strategic Research and Innovation Agenda for Personalised Medicine, SRIA for PM

Speaker

Dr. Monika Frenzel





Co-funded by
the European Union



“The Personalised Medicine Journey”

A joint effort

“The personalised medicine journey”



The ICPeMed Family

CSA – coordination and support actions

- European Regions (2x)
- Clinical trials in Personalised Medicine
- Health economics
- Prevention in Personalised Medicine
- International collaboration:
1x Latin and Caribbean Countries, 2x China, 1x Africa




None of the current and future challenges for personalised medicine can be solved by any one player alone. All key players in the field need to work together across borders in order to solve the problems and progress in delivering personalised medicine to the citizen.

Increasing commitment and investment in personalised medicine

EU supports joint efforts and activities related to personalised medicine aiming to establishing Europe as a global leader in the field but also to foster cross boarder/international collaboration.

Increased efforts for personalised medicine research, innovation and implementation on European regional and national level but also in collaborations across countries and internationally.


The personalised medicine journey



New upcoming opportunities: European Partnerships

- Bringing together a broad range of actors.
- Working together towards a common vision, translated into concrete roadmaps and coordinate implementation of activities.
- Broad set of activities: Support research & innovation projects, develop synergies with national and regional programmes.
- Powerful approaches for providing solutions to global challenges and drive transformation.

Since FP7 and during Horizon 2020, the EU provided a budget of more than 3 Billion Euro into personalised medicine.



Strategic Research and Innovation Agenda (SRIA)

SRIA for PM, 2023



EP PerMed


European Partnership
for **Personalised Medicine**

Strategic Research and Innovation Agenda (SRIA)

All European Partnerships have to develop a SRIA

Contextualisation of the partnership.

Identification and elaboration of R&I priority areas (and activities fostering the development and implementation) for coordinated action.



SRIA for PM (2023), published on 28 April 2023



Have a look!

The SRIA for PM (2023) will support a wide range of stakeholders and experts to further develop programs, activities, and research towards personalised medicine and care, as well as prevention. In line with this mission, its main intention is to support the planned new European Partnership for Personalised Medicine.

The PM “System of Health”

Personalised medicine “**value continuum**” including key players and overarching aspects

Overall, the system must be considered as a “System of Health” where results from one element feed into the next steps, but also feedback to previous steps in the value chain, forming a cycle of knowledge and insights that flows in both directions.



EP PerMed
European Partnership
for **Personalised Medicine**

57 “Triplets of Action, short ToA”

Core elements of the SRIA for PM, 2023

“Triplets of Action, short **ToA**” defining challenges, objectives, and the expected outcome of actions to foster personalised medicine research and the implementation of innovative personalised medicine approaches.

Presented along the main areas crucial for an effective development of personalised medicine :

- Interdisciplinary research efforts,
- successful innovation,
- implementation into healthcare systems,

And overarching activities essential for personalised medicine development and implementation.



Overview of the main research areas relevant for personalised medicine


Research needs to be collaborative, interdisciplinary and across borders to maximise synergies.

Number and title of ToA



Challenge Here the specific challenge is briefly described

Objective Here the needed actions to achieve the outcome is described

Outcome Here the expected outcome is described



Contribution of research and innovation activities, as well as policy frameworks to the overall outcome



Together developing the future

Inclusive, transparent and open process

Organised by the Drafting Group (representatives of Member States) with support of the EC and the ICPeMed Secretariat



02/2022
Draft PM SRIA
Outline

Analysis of strategic personalised medicine (PM) documents

06/2022
Draft-1 PM SRIA
Document

Experts & Stakeholders

- Over 70 interviews/ reports
- Development of the “Triplets of Action”

11/2022
Draft-2 PM SRIA
Document

Online Consultation

- 129 persons from 21 countries filled the questionnaire
- 47 “Triplets of Action
- Validation and prioritisation of ToAs
- Collection of additional ToAs

11/2022
Final Draft PM
SRIA Document

01/2023
Pre-Final
PM SRIA Document

ICPeMed Workshop

- 57 “Triplets of Action

04/2023
PM SRIA
Publication

The EP PerMed proposal is directly connected/refers to the SRIA for PM, 2023

SRIA for PM: To be updated with support of the EP PerMed




EP PerMed

European Partnership
for **Personalised Medicine**

Speaker

Wolfgang Ballensiefen
DLR, Germany



Personalised Medicine: The evolution of healthcare to improve people's life

EP PerMed - Context


EP PerMed builds on over 15 years of EU-funded consortia, initiatives & events, but also on a wide range national and European regional activities and efforts in all areas of the **Personalised Medicine (PM) Value Continuum**.

One central programme of the 11 “Family” members is the Spanish coordinated ERA PerMed a co-funded ERA-Net (2017- 2023) which supports over 110 transnational and interdisciplinary projects focussing on personalised medicine with several hundred research groups and a total joint investment of over 130 Mio €.




The International Consortium for Personalised Medicine

Overall aim: To coordinate and promote research along the full value chain to develop and evaluate personalised medicine approaches.




ICPerMed ‘Family’

This so called ICPerMed ‘Family’ has an important role in supporting the research and implementation of personalised medicine in Europe and beyond.




The European Partnership for Personalised Medicine

EP PerMed - Outlook



Executive Bodies



Next Steps


“The vision of EP PerMed is to improve health outcomes within sustainable healthcare systems through research, development, innovation and implementation of personalised medicine approaches for the benefit of patients, citizens, and society.”



Personalised Medicine – “Evolution in Movement”

“The evolution of healthcare to
improve people’s life”

Rapid increase of peer review
articles related to Personalised
Medicine (source PubMed).



Year	PM-related peer review articles, source PubMed
2005	365
2014	3.491
2015	4.871
2016	6.244
2017	7.683
2018	9.426
2019	11.501
2020	14.382
2021	17.636
2022	19.206
2023	14.890


Personalised Medicine – “Evolution in Movement”

Personalized Medicine Coalition (PMC),
Progress Report from 2017 and 2021:
Personalised Medicine related approvals
by FDA (in %)

In Germany **105** Personalised Medicine drugs are approved (German Association of Research-Based Pharmaceutical Companies, VFA).

In 2023 Romania's Chamber of Deputies adopted a *draft* law for supplementing Law no. 46/2003 on patients' rights, **giving each patient the right to personalised medicine**, based on a medical recommendation.

Year	% PM related approvals by FDA, source PMC
2005	5
2014	21
2015	28
2016	27
2017	34
2018	42
2019	25
2020	39



Thank you

How to get in contact with EP PerMed: eppermed@dlr.de

